The ‘Perfect Storm’ That Hampers Stewardship

Antimicrobial resistance continues to present a challenge to patient care for gram-negative bacterial infections, even with the approvals of newer agents, such as ceftolozane-tazobactam (Zerbaxa, Merck) and ceftazidime-avibactam (Avycaz, Allergan). The continued race against antimicrobial resistance has led to increasing efforts in